Neuroblastoma - Pipeline Review, H2 2016

Date: November 30, 2016
Pages: 366
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N02503ECBC0EN
Leaflet:

Download PDF Leaflet

Neuroblastoma - Pipeline Review, H2 2016
Neuroblastoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma – Pipeline Review, H2 2016, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 15, 1, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 9 and 4 molecules, respectively.Neuroblastoma.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Neuroblastoma Overview
Therapeutics Development
Neuroblastoma - Therapeutics under Development by Companies
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes
Neuroblastoma - Pipeline Products Glance
Neuroblastoma - Products under Development by Companies
Neuroblastoma - Products under Investigation by Universities/Institutes
Neuroblastoma - Companies Involved in Therapeutics Development
Neuroblastoma - Therapeutics Assessment
Drug Profiles
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Appendix 353

LIST OF TABLES

Number of Products under Development for Neuroblastoma, H2 2016
Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2016
Neuroblastoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2016
Neuroblastoma - Pipeline by Alissa Pharma, H2 2016
Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2016
Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2016
Neuroblastoma - Pipeline by Bayer AG, H2 2016
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2016
Neuroblastoma - Pipeline by Bionucleon Srl, H2 2016
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2016
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016
Neuroblastoma - Pipeline by Cebiotex SL, H2 2016
Neuroblastoma - Pipeline by Celgene Corp, H2 2016
Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H2 2016
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2016
Neuroblastoma - Pipeline by Codagenix, Inc., H2 2016
Neuroblastoma - Pipeline by CorMedix Inc, H2 2016
Neuroblastoma - Pipeline by Curis Inc, H2 2016
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2016
Neuroblastoma - Pipeline by EnGeneIC Ltd, H2 2016
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2016
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2016
Neuroblastoma - Pipeline by Green Cross Cell Corp, H2 2016
Neuroblastoma - Pipeline by Ignyta Inc, H2 2016
Neuroblastoma - Pipeline by Incuron, LLC, H2 2016
Neuroblastoma - Pipeline by Juno Therapeutics Inc, H2 2016
Neuroblastoma - Pipeline by Kolltan Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2016
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016
Neuroblastoma - Pipeline by MediaPharma srl, H2 2016
Neuroblastoma - Pipeline by Merck & Co Inc, H2 2016
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by Morphogenesis Inc, H2 2016
Neuroblastoma - Pipeline by Novartis AG, H2 2016
Neuroblastoma - Pipeline by Novogen Ltd, H2 2016
Neuroblastoma - Pipeline by OGD2 Pharma SAS, H2 2016
Neuroblastoma - Pipeline by Pfizer Inc, H2 2016
Neuroblastoma - Pipeline by Pharmacyclics Inc, H2 2016
Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by ProNAi Therapeutics Inc, H2 2016
Neuroblastoma - Pipeline by Recombio SL, H2 2016
Neuroblastoma - Pipeline by Ribomic Inc., H2 2016
Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H2 2016
Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2016
Neuroblastoma - Pipeline by Shionogi & Co Ltd, H2 2016
Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H2 2016
Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Neuroblastoma - Dormant Projects, H2 2016
Neuroblastoma - Dormant Projects (Contd..1), H2 2016
Neuroblastoma - Dormant Projects (Contd..2), H2 2016
Neuroblastoma - Dormant Projects (Contd..3), H2 2016
Neuroblastoma - Discontinued Products, H2 2016 354

LIST OF FIGURES

Number of Products under Development for Neuroblastoma, H2 2016
Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Neuroblastoma - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 383 pages
Sutro Biopharma, Inc. - Product Pipeline Review - 2016 US$ 1,275.00 Feb, 2016 · 34 pages
Fibrosarcoma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 64 pages
Malignant Pleural Mesothelioma - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 319 pages

Ask Your Question

Neuroblastoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: